Patents by Inventor Véronique Blanc
Véronique Blanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200408765Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: ApplicationFiled: February 7, 2020Publication date: December 31, 2020Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
-
Publication number: 20170343550Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic rnyelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma.Type: ApplicationFiled: January 9, 2017Publication date: November 30, 2017Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
-
Publication number: 20150274824Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferrentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.Type: ApplicationFiled: February 19, 2015Publication date: October 1, 2015Inventors: Veronique BLANC, Claudia FROMAND, Fabienne PARKER, Jiawen HAN, Daniel TAVARES, Chonghui ZHANG, Min LI, Xiao-Mai ZHOU, Michel STREULI
-
Patent number: 9011863Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.Type: GrantFiled: July 8, 2011Date of Patent: April 21, 2015Assignee: Exelixis, Inc.Inventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
-
Patent number: 8992912Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.Type: GrantFiled: March 6, 2013Date of Patent: March 31, 2015Assignee: SanofiInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
-
Publication number: 20140271665Abstract: The present invention provides methods of treating cancer by administering a compound of formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with an inhibitor that targets HER2 and/or HER3.Type: ApplicationFiled: July 8, 2011Publication date: September 18, 2014Applicants: Exelixis, Inc., Sanofi, Vanderbilt UniversityInventors: Dana T. Aftab, Carlos L. Arteaga, Veronique Blanc, Anindita Chakrabarty, Marielle Chiron-Blonde, Celine Nicolazzi, Ariella Hanker, Loic Vincent
-
Publication number: 20130302316Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.Type: ApplicationFiled: March 6, 2013Publication date: November 14, 2013Inventors: Veronique BLANC, Claudia FROMOND, Fabienne PARKER, Jiawen HAN, Daniel TAVARES, Chonghui ZHANG, Min LI, Xiao-Mai ZHOU, Michel STREULI
-
Patent number: 8460667Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.Type: GrantFiled: July 13, 2007Date of Patent: June 11, 2013Assignee: SanofiInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
-
Publication number: 20120156218Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.Type: ApplicationFiled: February 14, 2012Publication date: June 21, 2012Applicant: SANOFI-AVENTISInventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
-
Patent number: 8153765Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: GrantFiled: October 16, 2007Date of Patent: April 10, 2012Assignee: Sanof AventisInventors: Peter U. Park, Laura M. Bartle, Anna Skaletskaya, Viktor Golmakher, Daniel Tavares, Jutta Deckert, Vincent Mikol, Veronique Blanc
-
Publication number: 20110262454Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: ApplicationFiled: March 23, 2011Publication date: October 27, 2011Applicant: SANOFI-AVENTISInventors: Peter U. PARK, Laura BARTLE, Anna SKALETSKAYA, Viktor GOLMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MILOL, Veronique BLANC
-
Publication number: 20100047257Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors.Type: ApplicationFiled: July 13, 2007Publication date: February 25, 2010Applicant: SANOFI-AVENTISInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli
-
Publication number: 20090304710Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: ApplicationFiled: October 16, 2007Publication date: December 10, 2009Applicant: SANOFI-AVENTISInventors: Peter U. Park, Laura M. Bartle, Anna Skaletskaya, Viktor Golmakher, Daniel Tavares, Jutta Deckert, Vincent Mikol, Veronique Blanc
-
Patent number: 7090999Abstract: The invention concerns methods for preparing pristinamycin IIA or IIB.Type: GrantFiled: November 20, 2003Date of Patent: August 15, 2006Assignee: sanofi-aventisInventors: Veronique Blanc, Francis Blanche, Joel Crouzet, Nathalie Jacques, Patricia Lacroix, Denis Thibaut, Monique Zagorec, Laurent Debussche, Valerie De Crecy-Lagard
-
Patent number: 6833382Abstract: Novel group B streptogramin-like compounds of general formula (I), and a method for preparing streptogramines by mutasynthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramins are disclosed. Novel nucleotide sequences involved in the biosynthesis of said precursors, and their uses, are also disclosed.Type: GrantFiled: November 15, 2001Date of Patent: December 21, 2004Assignee: Aventis Pharma S.A.Inventors: Véronique Blanc, Denis Thibaut, Nathalie Bamas-Jacques, Francis Blanche, Joël Crouzet, Jean-Claude Barriere, Laurent Debussche, Alain Famechon, Jean-Marc Paris, Gilles Dutruc-Rosset
-
Publication number: 20040229236Abstract: The invention concerns methods for preparing pristinamycin IIA or IIB.Type: ApplicationFiled: November 20, 2003Publication date: November 18, 2004Applicant: Aventis PharmaInventors: Veronique Blanc, Francis Blanche, Joerl Crouzet, Nathalie Jacoues, Patricia Lacroix, Denis Thibaut, Monique Zagorec, Laurent Debussche, Valerie De Crecy-Lagard
-
Patent number: 6670157Abstract: The invention concerns methods for preparing pristinamycin IIB and methods for preparing modified pristinamycin IIB.Type: GrantFiled: August 9, 2000Date of Patent: December 30, 2003Assignee: Aventis Pharma S.A.Inventors: Veronique Blanc, Francis Blanche, Joel Crouzet, Nathalie Jacques, Patricia Lacroix, Denis Thibaut, Monique Zagorec, Laurent Debussche, Valerie De Crecy-Lagard
-
Publication number: 20020142947Abstract: Novel group B streptogramine-like compounds of general formula (I), and a method for preparing streptogramines by muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines, are disclosed. Novel nucleotide sequences involved in the biosynthesis of said precursors, and their uses, are also disclosed.Type: ApplicationFiled: November 15, 2001Publication date: October 3, 2002Applicant: Aventis Pharma, S.A.Inventors: Veronique Blanc, Denis Thibaut, Nathalie Bamas-Jacques, Francis Blanche, Joel Crouzet, Jean-Claude Barriere, Laurent Debussche, Alain Famechon, Jean-Marc Paris, Gilles Dutruc-Rosset
-
Patent number: 6352839Abstract: The invention provides a method for preparing streptogramins using genetically-modified microorganisms to influence the biosynthesis of at least one of the precursors of the group B streptogramins. Cultures of the genetically-modified microorganisms are supplemented with a least one precursor that is different from the streptogramin precursor whose biosynthesis is altered and the streptogramins produced are recovered.Type: GrantFiled: March 20, 1997Date of Patent: March 5, 2002Assignee: Aventis Pharma S.A.Inventors: Véronique Blanc, Denis Thibaut, Nathalie Bamas-Jacques, Francis Blanche, Joël Crouzet, Jean-Claude Barriere, Laurent Debussche, Alain Famechon, Jean-Marc Paris, Gilles Dutruc-Rosset
-
Patent number: RE47123Abstract: Antagonistic antibodies that specifically bind to and inhibit Class A Eph receptors are provided. Also provided are cytotoxic conjugates, pharmaceutical compositions and kits comprising these antibodies.Type: GrantFiled: August 1, 2014Date of Patent: November 13, 2018Assignee: SANOFIInventors: Veronique Blanc, Claudia Fromond, Fabienne Parker, Jiawen Han, Daniel Tavares, Chonghui Zhang, Min Li, Xiao-Mai Zhou, Michel Streuli